Volume 77, Issue 11, Pages (June 2010)

Slides:

Advertisements

Similar presentations

Kamyar Kalantar-Zadeh Kidney International

Advertisements

Serum Leptin and Vascular Risk Factors in Obstructive Sleep Apnea

LDL cholesterol in CKD—to treat or not to treat?

Volume 138, Issue 5, Pages (November 2010)

Volume 81, Issue 5, Pages (March 2012)

Beta blockers in the management of chronic kidney disease

Mycobacterium tuberculosis infection of end-stage renal disease patients in Taiwan: a nationwide longitudinal study S.-Y. Li, T.-J. Chen, K.-W. Chung,

Meghan E. Sise, Andrew M. Courtwright, Richard N. Channick

Urinary ammonia and long-term outcomes in chronic kidney disease

F. Chung, R. Subramanyam, P. Liao, E. Sasaki, C. Shapiro, Y. Sun

Anemia management in chronic kidney disease

Volume 83, Issue 3, Pages (March 2013)

Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.

C-reactive protein and dialysis access

Reassessment of the care of the patient with chronic kidney disease

C-reactive protein and dialysis access

John P. Middleton, Patrick H. Pun Kidney International

Volume 54, Issue 2, Pages (August 1998)

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2 Robert N. Foley, Charles A. Herzog, Allan.

Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real? S. Andrulli, S. Di Filippo, F. Locatelli

Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis Sanjeev Kumar, Stanley L.-S. Fan, Martin.

Volume 80, Issue 4, Pages (August 2011)

Kamyar Kalantar-Zadeh Kidney International

Jeffrey C. Fink, Glenn M. Chertow Kidney International

The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age B.O. Eriksen, O.C. Ingebretsen Kidney International

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

Volume 80, Issue 9, Pages (November 2011)

Volume 73, Issue 5, Pages (March 2008)

Chronic Kidney Dysfunction in Patients Alive without Relapse 2 Years after Allogeneic Hematopoietic Stem Cell Transplantation Imad Abboud, Raphaël Porcher,

The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis Sai Subhodhini Reddy, Jean L. Holley

Volume 74, Issue 3, Pages (August 2008)

Volume 67, Issue 5, Pages (May 2005)

Volume 70, Issue 11, Pages (December 2006)

Volume 61, Issue 6, Pages (June 2002)

Volume 77, Issue 2, Pages (January 2010)

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Benefits of preserving residual renal function in peritoneal dialysis

Volume 78, Issue 10, Pages (November 2010)

LDL cholesterol in CKD—to treat or not to treat?

The analysis of survival data: the Kaplan–Meier method

Volume 76, Issue 6, Pages (September 2009)

Volume 81, Issue 5, Pages (March 2012)

Volume 73, Issue 12, Pages (June 2008)

Volume 76, Issue 6, Pages (September 2009)

Volume 80, Issue 12, Pages (December 2011)

Volume 69, Issue 12, Pages (June 2006)

Tilman B. Drüeke, Ziad A. Massy Kidney International

Volume 85, Issue 5, Pages (May 2014)

Alternate-day dialysis may be needed for hemodialysis patients

Nephrology Crossword: Peritoneal Dialysis

Randomized controlled study of biocompatible peritoneal dialysis solutions: Effect on residual renal function S.L.S. Fan, T. Pile, S. Punzalan, M.J.

Cardiovascular disease in pediatric chronic dialysis patients

Nephrology Crossword: Glomerulonephritis

Volume 76, Issue 8, Pages (October 2009)

Volume 62, Issue 4, Pages (October 2002)

Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival.

Volume 85, Issue 5, Pages (May 2014)

Lamivudine in hepatitis B-associated membranous nephropathy

Proteinuria in obstructive sleep apnea

Volume 74, Issue 11, Pages (December 2008)

Volume 72, Issue 2, Pages (July 2007)

Charles A. Herzog Kidney International

Volume 75, Issue 1, Pages (January 2009)

Irena Begaj, Sajan Khosla, Daniel Ray, Adnan Sharif

Volume 75, Issue 7, Pages (April 2009)

Volume 70, Issue 3, Pages (August 2006)

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Volume 87, Issue 6, Pages (June 2015)

Prediction in idiopathic membranous nephropathy

Presentation transcript:

Volume 77, Issue 11, Pages 1031-1038 (June 2010) Sleep apnea is a novel risk predictor of cardiovascular morbidity and death in patients receiving peritoneal dialysis Sydney C.W. Tang, Bing Lam, Tzy Jyun Yao, Wah Shing Leung, Chung Ming Chu, Yiu Wing Ho, Mary S.M. Ip, Kar Neng Lai Kidney International Volume 77, Issue 11, Pages 1031-1038 (June 2010) DOI: 10.1038/ki.2010.76 Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 1 Median apnea-hypopnea indices (AHIs) for patients with baseline AHI <15/h (N=42) and AHI ≥15/h (N=51). Box, line across, and whiskers indicate first and third quartiles, median, and range, respectively. Kidney International 2010 77, 1031-1038DOI: (10.1038/ki.2010.76) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 2 Kaplan–Meier estimates of patient survival according to baseline presence (apnea-hypopnea index (AHI) ≥15/h) or absence (AHI <15/h) of significant sleep apnea. Kidney International 2010 77, 1031-1038DOI: (10.1038/ki.2010.76) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 3 Kaplan–Meier estimates of cardiovascular event-free survival according to baseline presence (apnea-hypopnea index (AHI) ≥15/h) or absence (AHI <15/h) of significant sleep apnea. Kidney International 2010 77, 1031-1038DOI: (10.1038/ki.2010.76) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 4 Box plots showing baseline apnea-hypopnea indices (AHIs) in patients who died (N=30) and those who were alive (N=63) during follow-up. Box, line across, and whiskers indicate first and third quartiles, median, and 10th and 90th percentiles, respectively. Kidney International 2010 77, 1031-1038DOI: (10.1038/ki.2010.76) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 5 Box plots showing baseline apnea-hypopnea indices (AHIs) in patients with one or more subsequent cardiovascular events (N=53) and those without (N=40) during follow-up. Box, line across, and whiskers indicate first and third quartiles, median, and 10th and 90th percentiles, respectively. Kidney International 2010 77, 1031-1038DOI: (10.1038/ki.2010.76) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 6 Flow diagram of patient recruitment process. COPD, chronic obstructive pulmonary disease; PSG, polysomnography. Kidney International 2010 77, 1031-1038DOI: (10.1038/ki.2010.76) Copyright © 2010 International Society of Nephrology Terms and Conditions